REG - Surgical Innovations - Notice of AGM and Posting of Annual Report

Surgical InnovationsAnnouncement

23/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW5238Pa&default-theme=true

RNS Number : 5238P  Surgical Innovations Group PLC  23 May 2024

Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

 

Notice of Annual General Meeting

Posting of 2023 Annual Report & Accounts

 

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and
distributor of innovative technology for minimally invasive surgery, confirms
that the Annual Report and Accounts for the year ended 31 December 2023 ("2023
Annual Report") and the Notice of the 2024 Annual General Meeting ("AGM") have
now been published and can be accessed via the "Investor Centre" section of
the Company's website at: www.sigroupplc.com (http://www.sigroupplc.com) .

 

The 2023 Annual Report, the Notice of AGM and details of voting by proxy have
been posted to shareholders who have not consented to receive electronic
communications.

 

Notice of AGM

The AGM is to be held on Monday 17 June 2024 at 11:00 am at the Company's
offices at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ and will
consider the Resolutions set out in the Notice of AGM.

 

The Company will broadcast its AGM on the Investor Meeting Company ("IMC")
platform and there will be an opportunity for investors to ask questions after
the formal business of the meeting concludes. Questions can also be pre
submitted via the IMC platform up until 16 June 2024 at 09:00 am or submitted
at any time during the AGM itself. Investors can sign up to IMC for free and
add to meet Surgical Innovations Group plc via:

 

https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor
(https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor)

 

Shareholders taking part via the IMC platform will not be able to speak or
vote on the AGM resolutions. Shareholders are therefore strongly encouraged to
exercise their voting rights by completing and submitting a Form of Proxy. It
is highly recommended that Shareholders submit their Form of Proxy as early as
possible to ensure that their votes are counted at the AGM. Shareholders are
strongly encouraged to appoint the Chairman as your proxy to ensure that each
shareholder's vote will be counted in the event of restrictions on
shareholders and proxies attending the AGM in person.

 

If you wish to attend the AGM in person and in your capacity as a shareholder
wish to vote on the day, please bring proof of shareholding or if shares are
held through a nominee account, a letter of representation, to facilitate your
voting rights.

 

 

For further information please contact:

 

 Surgical Innovations Group plc                       www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                     Tel: 0113 230 7597

 Singer Capital Markets (Nominated Adviser & Broker)                                      Tel: 020 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Charlotte Edgar                       Mob: 07980 541 893 / 07884 664 686

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist
products employed in laparoscopy, bariatric and metabolic surgery, hernia
repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM
partners and have also collaborated with a major UK industrial partner to
provide precision engineering solutions to complex problems outside the
medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a broad portfolio of cost
effective, procedure specific surgical instruments and implantable devices
that offer reliable solutions to genuine clinical needs in the operating
theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAQKBBBPBKDKPB